1. CytomX Therapeutics Appoints Charles S. Fuchs, Md, Mph to Board of Directors

    CytomX Therapeutics Appoints Charles S. Fuchs, Md, Mph to Board of Directors

    SAN FRANCISCO, Oct. 24, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing ...

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
  2. Quotes

    1. Dr. Fuchs' appointment to the CytomX Board reflects the continued progression of the organization as a clinical stage, oncology-focused company developing novel, high potential medicines for people with cancer.
    2. We are delighted to welcome Dr. Fuchs to our Board as we continue to advance our pipeline of Probody therapeutics for the treatment of cancer.
  3. Topics Mentioned